Comparing echocardiography and Cheetah NICOM for measuring stroke volume in adults with shock
Assessment of Stroke Volume in Shock Using Echocardiography Versus Bioreactive Impedance
University of Nevada, Las Vegas · NCT07020637
This study will test whether stroke volume measured by bedside ultrasound (transthoracic echocardiography) matches measurements from the Cheetah NICOM device in adults with shock.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Nevada, Las Vegas (other) |
| Locations | 1 site (Las Vegas, Nevada) |
| Trial ID | NCT07020637 on ClinicalTrials.gov |
What this trial studies
In this prospective observational protocol, adults admitted to the ICU with clinical signs of shock will have stroke volume measured by transthoracic echocardiography and by bioreactance-based Cheetah NICOM. Measurements will be recorded before and after a passive leg raising maneuver to capture both absolute values and directional changes. No therapeutic interventions are mandated by the protocol and all clinical care decisions remain with the treating team. The primary analysis will compare agreement between the two methods for absolute stroke volume and for predicting increases or decreases after passive leg raising.
Who should consider this trial
Good fit: Adults (≥18) admitted to the ICU within 24 hours with a clinical diagnosis of shock who can provide informed consent or have a legally authorized representative are eligible.
Not a fit: Patients with severe aortic valve disease or dynamic LVOT obstruction, morbid obesity precluding imaging, arrhythmias that affect stroke volume, implanted cardiac assist devices, pregnancy, or those on comfort-only care are excluded and unlikely to benefit from the measurement comparison.
Why it matters
Potential benefit: If Cheetah NICOM closely matches echocardiography, clinicians could use the noninvasive device for faster, continuous stroke volume monitoring to help guide resuscitation.
How similar studies have performed: Previous comparisons of bioreactance devices like NICOM to echocardiography or thermodilution have shown mixed results, with moderate agreement in some settings but variable accuracy in critically ill patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria * Age ≥ 18 years * Clinical diagnosis of shock as determined by the treating ICU physician (e.g., hypotension requiring vasopressors or evidence of end-organ hypoperfusion) * Able to obtain informed consent from the patient or a legally authorized representative * Enrollment within 24 hours of ICU admission Exclusion Criteria: * Pregnancy * Known severe aortic valve disease or dynamic left ventricular outflow tract obstruction * Morbid obesity (BMI \> 40) that precludes accurate echocardiographic imaging Presence of cardiac arrhythmias (e.g., atrial fibrillation with rapid ventricular response) affecting stroke volume measurements * Implanted cardiac assist devices (e.g., LVAD, pacemaker dependency) * Imminent death or decision for comfort care only
Where this trial is running
Las Vegas, Nevada
- University Medical Center Southern Nevada — Las Vegas, Nevada, United States (RECRUITING)
Study contacts
- Principal investigator: Mutsumi J Kioka, Medical Doctor — UNLV
- Study coordinator: Mutsumi J Kioka, Medical Doctor
- Email: mutsumi.kioka@unlv.edu
- Phone: 7026712345
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Shock, Critical Illness, Cheeta NICOM, Bioreactance, Transthoracic Echocardiography, Passive Leg Raising, Stroke Volume, Shock Assssment